| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14760584.5.5.617 |
| P698 | PubMed publication ID | 17181436 |
| P2093 | author name string | Piyush Patel | |
| Anne Marie F Salapatek | |||
| P2860 | cites work | Hay fever, hygiene, and household size | Q24674856 |
| The allergy adjuvant effect of particles - genetic factors influence antibody and cytokine responses | Q24816497 | ||
| Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. | Q30730983 | ||
| Long-term clinical efficacy of grass-pollen immunotherapy | Q33870492 | ||
| Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies | Q33915568 | ||
| Review of L-tyrosine confirming its safe human use as an adjuvant | Q34923189 | ||
| Taking toll: lipid A mimetics as adjuvants and immunomodulators | Q34960326 | ||
| Clinical practice. Allergic rhinitis. | Q36305258 | ||
| Allergic rhinitis: impact of the disease and considerations for management | Q36323437 | ||
| Modern approaches to therapeutic vaccination as treatment for type 1 respiratory hypersensitivity (allergy) treatment | Q36383791 | ||
| Immunological mechanisms of specific allergen immunotherapy | Q36448741 | ||
| Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy | Q39377481 | ||
| Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents | Q39667736 | ||
| Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood | Q40488834 | ||
| Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. | Q40511372 | ||
| Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). | Q40588482 | ||
| A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections | Q43650387 | ||
| A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. | Q43812891 | ||
| Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. | Q44574133 | ||
| Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant | Q50107849 | ||
| Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. | Q51722809 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 617-629 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine | |
| P478 | volume | 5 |
| Q37841682 | 100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). |
| Q42713288 | A Fusion Protein Consisting of the Vaccine Adjuvant Monophosphoryl Lipid A and the Allergen Ovalbumin Boosts Allergen-Specific Th1, Th2, and Th17 Responses In Vitro |
| Q37123463 | Allergy vaccines: dreams and reality |
| Q38541185 | Controlled Allergen Challenge Facilities and Their Unique Contributions to Allergic Rhinitis Research |
| Q104616199 | Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study |
| Q38284820 | Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety |
| Q41156645 | MPLA shows attenuated pro-inflammatory properties and diminished capacity to activate mast cells in comparison with LPS. |
| Q37642613 | Mucosal vaccines: recent progress in understanding the natural barriers. |
| Q38883770 | New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy |
| Q37812128 | Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens |
| Q44240760 | Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis |
| Q37989884 | Prophylactic and therapeutic implications of toll-like receptor ligands |
| Q26801862 | The expanding role of immunopharmacology: IUPHAR Review 16 |
| Q37567423 | Therapeutic manipulation of immune tolerance in allergic disease |
| Q37853197 | Toll-like receptor modulators: a patent review (2006-2010). |
| Q40135722 | Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis |
| Q41273420 | Update in the mechanisms of allergen-specific immunotheraphy |
| Q36171745 | Update on toll-like receptor-directed therapies for human disease |
Search more.